• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Herpes labialis: An Update.
CONCLUSION: For episodic treatment, oral antiviral agents, such as acyclovir (Zovirax), valacyclovir (Valtrex) and famciclovir (Famvir), are superior to topical antiviral therapy. Valacyclovir and famciclovir have greater oral bioavailability and are better absorbed than acyclovir, require less frequent dosing, but are more expensive and are not approved for children. Topical antiviral agents such as 5% acyclovir cream/ointment (Zovirax) ± hydrocortisone (Xerese), 1% penciclovir (Denavir) cream, and 50 mg Buccal Adhesive Tablet (ABT-50 mg) can also be used for episodic treatment of herpes labialis. These topical agents ar...
Source: Recent Patents on Inflammation and Allergy Drug Discovery - October 5, 2017 Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research

New approaches to chikungunya virus vaccine development.
Authors: Garcia A, Diego L, Judith B Abstract Chikungunya virus (CHIKV) is a mosquito-borne human pathogen that affects millions of individuals each year by causing non-specific flu-like symptoms, with a characteristic rash accompanied by joint pain that may last for a long time after the resolution of the infection. Despite intense research efforts, no approved vaccine or antiviral therapy is yet available. This review is based on articles retrieved by PubMed and clinical trials since 1980 to present. Virus complexity, protective and non-protective immune responses against the virus, and the most important a new p...
Source: Recent Patents on Inflammation and Allergy Drug Discovery - June 4, 2015 Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research

HIV 'gene hack' offers new treatment hope
ConclusionThis phase one trial showed that the infusion of genetically modified T helper cells was achieved reasonably safely in 12 people with chronic HIV.It isn’t clear if it could be an effective treatment for HIV, as the virus became detectable in the blood of all six participants who stopped taking their antiretroviral treatment. Although the levels of the virus then began to reduce after eight weeks, it only came back to undetectable levels in the person who already had one DNA strand of the genetic mutation. It took several weeks for this to happen in the other five people.The primary aim of the study was to deter...
Source: NHS News Feed - March 6, 2014 Category: Consumer Health News Tags: Medication Source Type: news